Industry: Healthcare
Published Date: August-2024
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 170
Report ID: PMRREP34717
The global preclinical imaging market is anticipated to increase from US$4.3 Bn in 2024 to US$5.96 Bn by the end of 2031. The market is expected to expand at a CAGR of 4.55% during the forecast period from 2024 to 2031.
Key Highlights of the Market
|
Attributes |
Key Insights |
|
Preclinical Imaging Market Size (2024E) |
US$4.3 Bn |
|
Projected Market Value (2031F) |
US$5.96 Bn |
|
Forecast Growth Rate (CAGR 2024 to 2031) |
4.55% |
|
Historical Growth Rate (CAGR 2019 to 2023) |
4.0% |
The preclinical imaging market involves the use of imaging techniques to study diseases and test new treatments in animal models before they are used in humans. This market is crucial for drug development and medical research.
Some of the major market trends include-
AI is increasingly being integrated into preclinical imaging to process and analyse large volumes of imaging data. This helps researchers gain valuable insights more quickly and accurately. Both private and public organizations are boosting their funding for preclinical research, driving the adoption of advanced imaging technologies.
North America is currently dominating the market due to its well-established players and significant funding for preclinical research. However, the Asia-Pacific region is also emerging as a significant market due to increasing drug development activities.
The market faces challenges due to regulations on animal testing, which is leading to the adoption of alternative methods like in-vitro tests and computer-based models.
Techniques like fluorescence and bioluminescence imaging have become popular for studying molecular and cellular processes in vivo. This modality allows real-time imaging of small animals, providing detailed images of blood flow and cardiac function.
Preclinical imaging continues to evolve, with ongoing advancements in technology and applications, making it an indispensable tool in drug development, disease research, and the development of clinical imaging paradigms.
Preclinical imaging has a fascinating history, evolving significantly over the years. Initially, it was seen as a niche technique with limited applications, but it has now become a crucial tool in medical research.
The preclinical imaging market witnessed growth in the past contributing to 3.7% to 3.9% compound annual growth rate over five years from 2013 to 2018. The market growth expected during 2024-2031 is 4.55%.
COVID-19 Impact Analysis
During the pandemic, clinical operations faced significant disruptions. Academic medical centers and universities swiftly shut down scientific research activities to ensure social distancing and minimize infection spread among research staff and others.
Researchers in radiology grappled with these challenges, affecting both ongoing and future imaging studies. However, as travel restrictions eased and sanitary precautions improved, many businesses resumed operations.
Euro-BioImaging Nodes tailored their services to the COVID-19 context, providing support to external users. Euro-BioImaging collaborated with EU-OPENSCREEN for COVID-19-related research, including drug screening projects using picture data exchange.
MILabs enhanced their preclinical diagnostic U-CT system for in vivo imaging of COVID-19 animal models, anticipating increased demand for antiviral research tools and vaccine testing. COVID-19 posed challenges, adaptations and ongoing research efforts continue to shape the preclinical imaging landscape.
The preclinical imaging market is poised for robust growth, driven by technological advancements, increased R&D investments, and evolving regulatory landscapes. North America currently holds the largest market share, but regions like Europe, and Asia Pacific are expected to see faster growth due to increasing research activities and technological adoption.
Technological Advancements
Innovations in imaging devices, such as hybrid imaging systems, have significantly enhanced the capabilities and accuracy of preclinical imaging. The rising incidence of chronic diseases like cancer, cardiovascular, and neurological disorders has led to an increase in drug trials, boosting the demand for preclinical imaging.
Growth of Contract Research Organizations (CROs)
The expansion of CROs has facilitated more preclinical projects, contributing to market growth. Well-developed research infrastructure and the availability of skilled professionals, especially in regions like North America, support the market. The increasing use of in-vivo imaging systems in preclinical research is another significant driver.
High Costs, and Regulatory Prohibitions
The installation and operational costs of developed preclinical imaging machinery are significant. Strict protocols governing preclinical research, including animal testing, can be time-consuming and complex. There is a shortage of skilled professionals to handle advanced imaging equipment. Insufficient infrastructure to support advanced imaging technologies can also be a barrier. Moreover, boundaries on animal testing by animal rights organizations and the push for non-invasive techniques can limit the scope of preclinical imaging.
Increased Funding and Investments
There is a growing number of investments in research and development, particularly in the pharmaceutical and biotechnology sectors. This funding supports the adoption of innovative imaging technologies.
Regulatory Support and Compliance
Adherence to 3R (Replacement, Reduction, and Refinement) measures in animal research is promoting the use of preclinical imaging, which assists in reducing biological variability and the number of animals required for studies.
Optical Imaging Segment Contributes a Major Market Share
|
Category |
Market Share through 2023 |
|
Optical Imaging Segment |
13.6% |
The optical imaging segment held the largest revenue share in the preclinical imaging market, accounting for 13.6% in 2022. This is largely due to its extensive use in small animal imaging and new drug discovery projects.
Optical imaging is indeed a crucial technology in the preclinical imaging market. Its ability to provide detailed images of biological processes in live animals makes it invaluable for research and development. The dominance of this segment is attributed to advantages like cost effectiveness, non-invasive and real-time imaging, ease of use, and wide application.
Optical imaging techniques, such as bioluminescence and fluorescence, allow for non-invasive and real-time visualization of biological processes in small animals. This is crucial for monitoring disease progression and evaluating the efficacy of new drugs.
Compared to other imaging modalities like MRI or PET, optical imaging is comparatively cost-effective. This makes it more accessible for a wide range of research applications.
Continuous improvements in optical imaging technologies have improved their sensitivity and resolution, making them more effective for complete molecular and cellular imaging.
Optical imaging is widely used in various fields, including oncology, neurology, and cardiovascular research. Its versatility in different exploration areas contributes to its dominant market share. The effortlessness and rapidity of optical imaging techniques make them user-friendly, encouraging their widespread adoption in preclinical studies.
R&D to Exhibit Substantial Revenue Growth
|
Category |
Market Share through 2023 |
|
Research & Development |
54.93% |
The preclinical imaging market is experiencing significant growth, mainly in the research and development (R&D) segment. This advancement is driven by technological improvements and improved healthcare infrastructure.
Preclinical imaging is important for studying disease processes and testing potential treatments in animal models before they are used in humans. The increasing demand for non-invasive small animal imaging techniques is a significant driver for this market.
Innovation is the heartbeat of any field, and preclinical imaging is no exception. R&D efforts drive the development of cutting-edge imaging modalities—from traditional techniques like CT scans and MRI to newer ones like optical imaging, and PET scans.
Scientists work on a mission to unravel the mysteries of diseases, test potential treatments, and understand biological processes. R&D in preclinical imaging allows researchers to peek inside living organisms-mice, rats, and other critters-without invasive procedures. It is like having a tiny window into their bodies.
This non-invasive approach reduces the need for euthanizing animals just for study purposes. It aligns beautifully with the 3Rs principle: Replacement, Reduction, and Refinement. Less animal suffering, more data.
R&D fuels the progress in decoding disease pathways, tracking drug effects, and predicting treatment outcomes. It’s like adding turbo boosters to the scientific engine. By studying disease models in vivo (inside a living organism), researchers gain insights that can directly impact human health. It’s like solving a puzzle where each piece represents a potential breakthrough.
Researchers now process the colossal amount of imaging data using AI algorithms. These digital brains help them spot patterns, identify anomalies, and accelerate discoveries. For instance, Koninklijke Philips N.V. introduced the Philips CT 3500-a high-throughput CT system. It is like the superhero of CT scans, optimized for large-scale screening initiatives and radiology. Faster diagnoses, better efficiency.
Strict regulations limit animal testing. Animal rights organizations ensure our furry friends are treated kindly. So, researchers are turning to alternatives: in-vitro tests, micro-dosing, computer models, and virtual drug testing. It is like shifting from a physical map to a GPS-different routes, same destination. In a nutshell, R&D in preclinical imaging isn’t just about fancy machines; it’s about unlocking secrets, saving lives, and making science cooler.
North America to Take Charge in the Market
|
Region |
Market Share through 2023 |
|
North America |
35.7% |
North America is currently the dominant region in the preclinical imaging market, accounting for over 35.7% of the market share in 2023. This dominance is driven by increasing drug development activities and a rising demand for non-invasive techniques to study disease pathology.
Companies in the preclinical imaging market adopt several key approaches to enhance their market presence and drive growth. Companies frequently introduce new and advanced imaging systems to meet the evolving needs of preclinical research. For example, Revvity, Inc. recently unveiled new imaging systems like the IVIS Spectrum 2 and Quantum GX3 microCT.
Key Industry Developments
In Jul 2024, MILabs enhanced their U-CT system for in-vivo imaging of COVID-19 animal models. This system offers ultra-high-resolution non-invasive lung imaging, allowing precise localization of diseased processes in small animals.
In May 2023, Koninklijke Philips N.V. introduced the Philips CT 3500, an innovative high-throughput CT system designed for large-scale screening initiatives and regular radiology. It incorporates advanced image reconstruction capabilities and workflow enhancements, ensuring reliable diagnoses and operational efficiency even in demanding medical environments
In May 2022, Bruker launched innovative magnetic resonance imaging (MRI) devices, including high-field magnets (7.4 Tesla and 9.4 Tesla) that form part of their market-leading preclinical MRI systems
|
Attributes |
Details |
|
Forecast Period |
2024 to 2031 |
|
Historical Data Available for |
2019 to 2023 |
|
Market Analysis |
US$ Million for Value |
|
Key Regions Covered |
|
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon request |
By Product Type
By Application
By End User
By Region
To know more about delivery timeline for this report Contact Sales
Increasing investments and funding in research and development, prominence of non-invasive modalities etc. are expected to rise the market demand.
Some of the prominent players operating in the market are Bruker Corporation, Perkin Elmer Inc. etc.
North America to stand out in the market.
The growing number of investments and funding in research and development, particularly for non-invasive small animal imaging techniques is an opportunity for market development.
The optical imaging segment exhibits a substantial contribution to the market.
